UQ’s BASE facility and biotechnology company Vaxxas have been announced as stage winners of a prestigious global prize to accelerate a patch-based mRNA vaccine for COVID-19.

UQ’s BASE facility and biotechnology company Vaxxas have been announced as stage winners of a prestigious global prize to accelerate a patch-based mRNA vaccine for COVID-19.

This license enables Vaxxas to prepare for a clinical trial of the first Respiratory Syncytial Virus (RSV) vaccine delivered to the skin using Vaxxas’ novel high-density microarray patch (HD-MAP). Licensed to Vaxxas for worldwide use, this next-generation vaccine antigen (DS2)...

Vaxxas is commercializing a novel needle-free vaccination technology that enhances the performance of existing and next-generation vaccines.

Vaxxas CEO David Peacock says Trump-ordered MMR vaccine separation could take 10 years. Vaccine consultant Bill Gruber calls it a

ANFF helps its industry partners develop real, usable technologies by giving them access to the right tools and expert support. Across the country, industry leaders are using this support to advance b...

Chris McMillan and Chloe Entriken of the University of Queensland, Australia, take us behind the scenes of their latest publication&nbsp;<a href="http://doi.org/10.1099/jgv.0.002179">&#39;Improved eff...

“My journey from academia to industry" Date:  Thursday November 7th Speaker: Dr. Sandra Depelsenaire, Vaxxas, Australia Join Webinar here Skills and Opportunities for Early Career Researchers...

Welcome to our new weekly round-up of Australian startup raises, in a collaboration between Startup Daily and our sister publication, SmartCompany. The last week of August features 5 startups spanning vaccine delivery, logistics and cross-border payments, which collectively raised $95.45 million. (A shoutout to our cousins across The Ditch too, where the former Kiwi TikTok boss raised a NZ$3.8 million Seed round for Aether.) Here they are the Australian raises: Vaxxas: $49.2 million Source: Vaxxas Needle-free vaccination delivery scaleup Vaxxas has raised $49.2 million in a Series D, but cut 10% of its workforce, including a clear-out of its executives.

UQ’s BASE facility and biotechnology company Vaxxas have been announced as stage winners of a prestigious global prize to accelerate a patch-based mRNA vaccine for COVID-19.

The U.S. Patent and Trademark Office issues a patent to Vaxxas covering manufacturing technology for its microarray patch.

Vaxxas has received a manufacturing licence from Australia’s Therapeutic Goods Administration (TGA) for its high-density microarray patch (HD-MAP).

Vaxxas, a biotechnology company, has secured almost $90 million in new funding to accelerate the commercialisation of its high-density microarray patch (HD-MAP) for needle-free vaccine delivery. This is said to be a “major advance” in vaccine delivery, enabling needle-free administration that reduces temperature control requirements for vaccine storage and creates opportunities for self-administration in the […]

Brisbane-based Vaxxas has raised ~A$90m (A$49.22m Series D equity plus a A$40m debt facility), extending its cash runway into the second half of 2027, and

Plus, news about Vaxxas, Mid-Atlantic BioTherapeutics, Incyclix Bio and Invivyd.

Welcome to our new weekly round-up of Australian startup raises, in a collaboration between Startup Daily and our sister publication, SmartCompany. The last week of August features 5 startups spanning vaccine delivery, logistics and cross-border payments, which collectively raised $95.45 million. (A shoutout to our cousins across The Ditch too, where the former Kiwi TikTok boss raised a NZ$3.8 million Seed round for Aether.) Here they are the Australian raises: Vaxxas: $49.2 million Source: Vaxxas Needle-free vaccination delivery scaleup Vaxxas has raised $49.2 million in a Series D, but cut 10% of its workforce, including a clear-out of its executives.

Study Aims to Validate Thermostable, Self-Administered MVA-Vaccine Platform for Pandemic Preparedness and Global Immunization ATLANTA, GA - July 28, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GO...